VINC has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
VINC has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2025-03-24), Vincerx Pharma's share price is $0.64. Vincerx Pharma's Book Value per Share for the quarter that ended in Sep. 2024 was $5.80. Hence, Vincerx Pharma's PB Ratio of today is 0.11.
The historical rank and industry rank for Vincerx Pharma's PB Ratio or its related term are showing as below:
During the past 5 years, Vincerx Pharma's highest PB Ratio was 12.98. The lowest was 0.00. And the median was 0.00.
During the past 12 months, Vincerx Pharma's average Book Value Per Share Growth Rate was -60.60% per year. During the past 3 years, the average Book Value Per Share Growth Rate was -33.90% per year.
During the past 5 years, the highest 3-Year average Book Value Per Share Growth Rate of Vincerx Pharma was -33.90% per year. The lowest was -33.90% per year. And the median was -33.90% per year.
The historical data trend for Vincerx Pharma's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vincerx Pharma Annual Data | |||||||||||
Trend | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | ||||||
PB Ratio | - | 11.52 | 2.14 | 0.45 | 2.25 |
Vincerx Pharma Quarterly Data | |||||||||||||||||||
Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | |
PB Ratio | Get a 7-Day Free Trial |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
1.37 | 2.25 | - | 1.56 | 2.47 |
For the Biotechnology subindustry, Vincerx Pharma's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Vincerx Pharma's PB Ratio distribution charts can be found below:
* The bar in red indicates where Vincerx Pharma's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
Vincerx Pharma's PB Ratio for today is calculated as follows:
PB Ratio | = | Share Price | / | Book Value per Share (Q: Sep. 2024) |
= | 0.64 | / | 5.801 | |
= | 0.11 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
PB Ratio | = | Market Cap | / | (Total Stockholders Equity | - | Preferred Stock) |
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Vincerx Pharma (NAS:VINC) PB Ratio Explanation
Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Thank you for viewing the detailed overview of Vincerx Pharma's PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
Alexander A. Seelenberger | officer: Chief Financial Officer | 4500 GREAT AMERICA PKWY, STE. 100 #29, SANTA CLARA CA 95054 |
Raquel E. Izumi | director, 10 percent owner, officer: Chief Operations Officer | 4500 GREAT AMERICA PKWY, STE. 100 #29, SANTA CLARA CA 95054 |
Ahmed Md Hamdy | director, 10 percent owner, officer: President and CEO | 995 EAST ARQUES AVENUE, SUNNYVALE CA 94085 |
Tom C Thomas | officer: See Remarks | 180 LOMA ALTRO, C/O MOCON INC, LOS GATOS CA 95030 |
Christopher P. Lowe | director | 2511 N LOOP 1604,, SUITE 204, SAN ANTONIO TX 78258 |
Laura I. Bushnell | director | 4500 GREAT AMERICA PKWY, STE. 100 #29, SANTA CLARA CA 95054 |
Rubric Capital Management Lp | 10 percent owner | 155 EAST 44TH ST, SUITE 1630, NEW YORK NY 10017 |
David Efraim Rosen | 10 percent owner | 155 EAST 44TH ST., SUITE 1630, NEW YORK NY 10017 |
Sooin Hwang | officer: Chief Business Officer | 260 SHERIDAN AVENUE, SUITE 400, PALO ALTO CA 94306 |
Xiaoming Zhang | officer: Chief Technology Officer | 260 SHERIDAN AVE, SUITE 400, PALO ALTO CA 94306 |
Ruth E. Stevens | director | 260 SHERIDAN AVENUE, SUITE 400, PALO ALTO CA 94306 |
Garban Hermes De Jesus | officer: Chief Medical Officer | 4500 GREAT AMERICA PKWY, STE. 100 #29, SANTA CLARA CA 95054 |
John C. Byrd | 10 percent owner | 4500 GREAT AMERICA PKWY, STE. 100 #29, SANTA CLARA CA 95054 |
Brian Druker | director | ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA 91320-1799 |
John H. Lee | director | 4500 GREAT AMERICA PKWY, STE. 100 #29, SANTA CLARA CA 95054 |
From GuruFocus
By Business Wire • 01-06-2025
By Marketwired • 08-08-2024
By GlobeNewswire • 12-27-2024
By Business Wire • 12-30-2024
By Marketwired • 05-14-2024
By Marketwired • 01-29-2025
By Marketwired • 04-26-2024
By GlobeNewswire • 01-07-2024
By Marketwired • 01-02-2025
By Marketwired • 12-04-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.